XML 120 R48.htm IDEA: XBRL DOCUMENT v3.25.4
SHARE-BASED PAYMENTS (Tables)
12 Months Ended
Dec. 31, 2025
Disclosure of terms and conditions of share-based payment arrangement [abstract]  
Schedule of expense recognized from share based payment transactions
Share-based payment expense, which is classified as selling, general, and administrative expenses on the consolidated statement of income and loss and comprehensive income and loss was as follows:
For the year ended December 31,
In millions202520242023
Restricted and performance share units$29.1 $12.1 $— 
Equity-settled share options8.1 7.4 10.7 
Cash-settled awards— 1.8 35.3 
Total$37.2 $21.3 $46.0 
The following table summarizes the activity in RSUs and PSUs for employees and non-employee directors during the years ended December 31, 2025 and December 31, 2024:
20252024
RSUsPSUsRSUsPSUs
Number of unitsWeighted Average Grant Date Fair ValueNumber of unitsWeighted Average Grant Date Fair ValueNumber of unitsWeighted Average Grant Date Fair ValueNumber of unitsWeighted Average Grant Date Fair Value
Outstanding at January 1,1,018,974$13.63 1,888,821$14.55 $— $— 
Granted during the year732,55327.69 1,208,39127.32 1,101,08513.632,012,59614.55
Vested during the year(380,949)13.84 (24,141)15.37 (21,079)13.64(16,412)14.55
Forfeited during the year(98,989)18.74 (202,986)18.82 (61,032)13.64(107,363)14.55
Outstanding at December 31,1,271,589$21.27 2,870,085$19.62 1,018,974$13.63 1,888,821$14.55 
Schedule of number and weighted-average exercise prices of share options
The number and weighted-average exercise prices of share options under the 2019 ESOP and 2023 ESOP were as follows:
2019 & 2023 ESOP:202520242023
Number of
options
Weighted
average
exercise price (USD)
Number of
options
Weighted
average
exercise price (USD) (1) (2)
Number of
options
Weighted
average
exercise price (USD) (1) (2)
Outstanding at January 1st
12,707,243$10.02 14,911,455$9.56 9,640,694$9.16 
Granted during the year— — 5,309,09410.30 
Forfeited during the year(201,148)9.48 (780,114)11.03 (38,333)10.55 
Exercised during the year(3,631,101)10.14 (1,424,098)8.48 — 
Outstanding at December 31st
8,874,9949.98 12,707,24310.02 14,911,4559.56 
Exercisable at December 31st
4,505,505$9.90 8,299,943$9.74 $— 
__________________________________________________
(1)Immediately prior to the completion of the IPO, the Company effected a 3.3269-for-1 share split of its ordinary shares (the “Share Split”). The number of options and weighted average exercise prices in the table above have been adjusted retrospectively to reflect the increase in the number of ordinary shares outstanding resulting from the Share Split. Refer to Note 18. Shareholders’ Equity for additional information.
(2)As a result of the change in currency of the exercise price, management converted the weighted average exercise price from EUR to USD for the years ended December 31, 2024 and 2023, respectively, to maintain the comparability of the disclosure.
Schedule of measurement of the fair values of equity-settled awards
The inputs used in the measurement of the fair values of equity-settled awards at the respective modification dates and the re-measurement of the fair values of cash-settled awards as of December 31, 2024 were as follows:
ESOP 2019 & 2023 PlansEquity-settled awardsCash-settled awards
Fair value at re-measurement dates:Remeasured fair value at December 31, 2024
Cash compensation payable of group performance-based optionsN/A
$0.22 - $4.92
Fair value of underlying share at re-measurement dates
$13.00 - $18.94
N/A
Exercise price
$7.70 - $14.19
N/A
Expected volatility
39.8% - 44.4%
42.2 %
Expected life
1.03 - 5.19 years
0.09 - 1.75 years
Expected dividends— %— %
Risk-fee interest rate
4.0% - 4.8%
4.6 %
The inputs used in the measurement of the fair values of equity-settled awards as at respective grant dates and the re-measurement of the fair values of cash- settled awards as of December 31, 2023 were as follows:
ESOP 2019 & 2023 Plans (1) (2)
Equity-settled awardsCash-settled awards
Fair value at grant dates (EUR):
Fair value at grant dates (USD):
Remeasured fair value at period end dates (EUR):Remeasured fair value at period end dates (USD):
Time vested options
€5.50 - €8.37
$6.07 - $9.25
€6.55 - €10.75
$7.24 - $11.87
Brand performance-based options
€5.13 - €6.87
$5.67 - $7.59
€5.61 - €10.98
$6.20 - $12.14
Group performance-based options
€1.74 - €3.23
$1.92 - $3.57
€7.38 - €7.51
$8.15 - $8.29
Fair value of underlying share at measurement dates
€12.40 - €14.02
$13.70 - $15.49
€17.13
$18.93
Exercise price
€7.09 - €9.68
$7.84 - $10.69
€7.09 - €12.92
$7.74 - $14.11
Expected volatility
40.3% - 45.5%
40.3% - 45.5%
40.0% - 44.0%
40.0% - 44.0%
Expected life
1.63 - 6.00 years
1.63 - 6.00 years
1.25 - 4.25 years
1.25 - 4.25 years
Expected dividends— %
—%
— %— %
Risk-free interest rate
2.3% - 3.2%
2.3% - 3.2%
2.0% - 2.9%
2.0% - 2.9%
________________________________________________
(1)Immediately prior to the completion of the IPO, the Company effected the Share Split. The share values in the table above have been adjusted retrospectively to reflect the increase in the number of ordinary shares outstanding resulting from the Share Split. Refer to Note 18. Shareholders’ Equity for additional information.
(2)On January 4, 2024, the exercise price currency of all options was converted from EUR to USD. The fair value inputs previously reported in EUR were converted to USD using the exchange rate on the date of the original grant (for the exercise price) or the rate as of December 31 of the disclosed period (for all other inputs disclosed in EUR) for purposes of comparability with current year information.